focus -WSS

focus

author：explore 2025-09-28 00:51:16 - browse：46398

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

hotspot

knowledge

WSS

Medicaid, Medicare dual

Some dementia cases could be undiagnosed liver disease

Intercept Pharmaceuticals sells itself for less than $1 billion

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Commercial surrogacy can be ethical, despite pope’s claims

focus

focus

knowledge

Activists slam private health insurers over coverage restrictions

Commercial surrogacy can be ethical, despite pope’s claims

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Time to name cancers by genetics, not organ of origin, expert says

Medical leaders decry Supreme Court decision on affirmative action

Medicare drug price negotiation program allowed for now

What does generative AI mean for health care? We asked experts

Even great ERs can’t make up for American health disparities

Drug repurposing or repositioning? The language matters

General Catalyst, Summa Health deal will turn on physician buy

hotspot

Biogen shutters digital health group, ends Apple study, in cost cutting move

Biogen shutters digital health group, ends Apple study, in cost cutting move

Intercept Pharmaceuticals sells itself for less than $1 billion

Ionis has late

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

focus

hotspot

knowledge

knowledge